This invention relates to double-stranded nucleic acids that reduce expression of the LDHA gene by targeting lactate dehydrogenase mRNA for use in the treatment of PHI, PH2, PH3 (primary hyperoxaluria Type 1, Type 2 or Type 3) or idiopathic hyperoxaluria, e.g., Dicer substrate siRNA (DsiRNA) agents.